Neonatal candidiasis: Diagnosis, prevention, and treatment

Journal of Infection

Volumn 69, Issue S1, 2014, Pages S19-S22

  Greenberg, Rachel G ^a   Benjamin, Daniel K ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antifungal therapy; Candida; Diagnosis; Neonatal intensive care unit; Prevention

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD CULTURE; CANDIDA; CANDIDIASIS; DRUG CHOICE; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG PENETRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY DIAGNOSIS; EARLY INTERVENTION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEWBORN; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; OUTCOME ASSESSMENT; PARENTERAL NUTRITION; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK FACTOR; TREATMENT DURATION; AGE;

AGE FACTORS; CANDIDIASIS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL;

EID: 84910002916     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.07.012     Document Type: Article

References (35)

1. Benjamin D.K., Stoll B.J., Gantz M.G., Walsh M.C., Sanchez P.J., Das A., et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics 2010, 126(4):e865-e873.
2. Cotten C.M., McDonald S., Stoll B., Goldberg R.N., Poole K., Benjamin D.K., et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006, 118(2):717-722.
3. Benjamin D.K., Stoll B.J., Fanaroff A.A., McDonald S.A., Oh W., Higgins R.D., et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117(1):84-92.
4. Benjamin D.K., Poole C., Steinbach W.J., Rowen J.L., Walsh T.J. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003, 112(3 Pt 1):634-640.
5. Jones J.M. Laboratory diagnosis of invasive candidiasis. Clin Microbiol Rev 1990, 3(1):32-45.
6. Berenguer J., Buck M., Witebsky F., Stock F., Pizzo P.A., Walsh T.J. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993, 17(2):103-109.
7. Schelonka R.L., Moser S.A. Time to positive culture results in neonatal Candida septicemia. J Pediatr 2003, 142(5):564-565.
8. Cohen-Wolkowiez M., Smith P.B., Mangum B., Steinbach W.J., Alexander B.D., Cotten C.M., et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007, 27(2):97-100.
9. Lamoth F., Cruciani M., Mengoli C., Castagnola E., Lortholary O., Richardson M., et al. beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012, 54(5):633-643.
10. Senn L., Robinson J.O., Schmidt S., Knaup M., Asahi N., Satomura S., et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008, 46(6):878-885.
11. Wahyuningsih R., Freisleben H.J., Sonntag H.G., Schnitzler P. Simple and rapid detection of Candida albicans DNA in serum by PCR for diagnosis of invasive candidiasis. J Clin Microbiol 2000, 38(8):3016-3021.
12. Morace G., Pagano L., Sanguinetti M., Posteraro B., Mele L., Equitani F., et al. PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol 1999, 37(6):1871-1875.
13. Saiman L., Ludington E., Pfaller M., Rangel-Frausto S., Wiblin R.T., Dawson J., et al. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 2000, 19(4):319-324.
14. Kaufman D., Boyle R., Hazen K.C., Patrie J.T., Robinson M., Donowitz L.G. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345(23):1660-1666.
15. Manzoni P., Stolfi I., Pugni L., Decembrino L., Magnani C., Vetrano G., et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356(24):2483-2495.
16. Wade K.C., Benjamin D.K., Kaufman D.A., Ward R.M., Smith P.B., Jayaraman B., et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J 2009, 28(8):717-723.
17. Greenberg R.G., Benjamin D.K., Gantz M.G., Cotten C.M., Stoll B.J., Walsh M.C., et al. Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis. J Pediatr 2012, 161(2). 264-9.e2.
18. Benjamin D.K., DeLong E.R., Steinbach W.J., Cotton C.M., Walsh T.J., Clark R.H. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 2003, 112(3 Pt 1):543-547.
19. Prasad P.A., Coffin S.E., Leckerman K.H., Walsh T.J., Zaoutis T.E. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 2008, 27(12):1083-1088.
20. Baley J.E., Meyers C., Kliegman R.M., Jacobs M.R., Blumer J.L. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990, 116(5):791-797.
21. Juster-Reicher A., Leibovitz E., Linder N., Amitay M., Flidel-Rimon O., Even-Tov S., et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants. Infection 2000, 28(4):223-226.
22. Ascher S.B., Smith P.B., Watt K., Benjamin D.K., Cohen-Wolkowiez M., Clark R.H., et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J 2012, 31(5):439-443.
23. Wurthwein G., Groll A.H., Hempel G., Adler-Shohet F.C., Lieberman J.M., Walsh T.J. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005, 49(12):5092-5098.
24. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.
25. Soltani M., Tobin C.M., Bowker K.E., Sunderland J., MacGowan A.P., Lovering A.M. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents 2006, 28(6):574-577.
26. Doby E.H., Benjamin D.K., Blaschke A.J., Ward R.M., Pavia A.T., Martin P.L., et al. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J 2012, 31(6):632-635.
27. Schwarze R., Penk A., Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res 2000, 5(5):203-208.
28. Wade K.C., Wu D., Kaufman D.A., Ward R.M., Benjamin D.K., Sullivan J.E., et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008, 52(11):4043-4049.
29. Piper L., Smith P.B., Hornik C.P., Cheifetz I.M., Barrett J.S., Moorthy G., et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 2011, 30(5):375-378.
30. Hope W.W., Smith P.B., Arrieta A., Buell D.N., Roy M., Kaibara A., et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010, 54(6):2633-2637.
31. Hope W.W., Mickiene D., Petraitis V., Petraitiene R., Kelaher A.M., Hughes J.E., et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008, 197(1):163-171.
32. Smith P.B., Walsh T.J., Hope W., Arrieta A., Takada A., Kovanda L.L., et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009, 28(5):412-415.
33. Heresi G.P., Gerstmann D.R., Reed M.D., van den Anker J.N., Blumer J.L., Kovanda L., et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006, 25(12):1110-1115.
34. Cohen-Wolkowiez M., Benjamin D.K., Piper L., Cheifetz I.M., Moran C., Liu P., et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther 2011, 89(5):702-707.
35. Saez-Llorens X., Macias M., Maiya P., Pineros J., Jafri H.S., Chatterjee A., et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009, 53(3):869-875.